Hepatocellular carcinoma after danazol therapy.
Danazol, an inhibitor of pituitary gonadotropin, has been proposed in the treatment of systemic lupus erythematosus (SLE). We report the case of a female patient with SLE in whom a hepatocellular carcinoma was discovered after 4 years of treatment with danazol. Except for 3 days of hypochondrium pain, there were neither clinical signs of liver tumor nor biological abnormalities. An ultrasonography showed 2 tumors of the liver. At histological examination after surgery, one of the tumors was found to be a benign adenoma, while the other was a well differentiated hepatocellular carcinoma. When longterm danazol therapy is required, ultrasonography may be useful for early tumor detection.
Weill
B J
BJ
Rheumatology Department, Hôpital Cochin, Paris, France.
Menkès
C J
CJ
Cormier
C
C
Louvel
A
A
Dougados
M
M
Houssin
D
D
D000236:Adenoma / Q000139:chemically induced / Q000175:diagnosis; D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced* / Q000175:diagnosis; D003613:Danazol / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D011245:Pregnadienes / Q000009:adverse effects*; D014463:Ultrasonography
D011245:Pregnadienes; D003613:Danazol